NCT00094497 · OUTCOME

Change in Quality of Life as Measured by QLQ-C30

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) · Source last updated 2016-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: units on a scale
Interval / dispersion: Standard Deviation
Time frame: baseline and 8 weeks

What was measured

scale ranged from 0 to 100 with higher score meaning greater quality of life

Analysis population: participants with data on both time points

Groups in this outcome

EDP-M

etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)

Sz-M

streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
EDP-M	60
Sz-M	39

Reported measurements

Source class 1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
EDP-M	-6.0	21.4	Not reported	Not reported	Not reported
Sz-M	-7.7	25.6	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
21.4
value
-6.0
group Id
OG001
spread
25.6
value
-7.7

denoms

counts
group Id
OG000
value
60
group Id
OG001
value
39
units
Participants

description

scale ranged from 0 to 100 with higher score meaning greater quality of life

dispersion Type

Standard Deviation

groups

description
etopodide, doxorubicin, cisplatin and mitotane Etoposide Doxorubicin Cisplatin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)
id
OG000
title
EDP-M
description
streptozotocin and mitotane Streptozotocin Mitotane participants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)
id
OG001
title
Sz-M

param Type

MEAN

population Description

participants with data on both time points

reporting Status

POSTED

time Frame

baseline and 8 weeks

title

Change in Quality of Life as Measured by QLQ-C30

type

SECONDARY

unit Of Measure

units on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice